Recombinant Proteins
"Recombinant Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins prepared by recombinant DNA technology.
| Descriptor ID |
D011994
|
| MeSH Number(s) |
D12.776.828
|
| Concept/Terms |
Recombinant Proteins- Recombinant Proteins
- Proteins, Recombinant
- Proteins, Biosynthetic
- Biosynthetic Proteins
Proteins, Recombinant DNA- Proteins, Recombinant DNA
- DNA Proteins, Recombinant
- Recombinant DNA Proteins
- DNA Recombinant Proteins
- Proteins, DNA Recombinant
- Recombinant Proteins, DNA
|
Below are MeSH descriptors whose meaning is more general than "Recombinant Proteins".
Below are MeSH descriptors whose meaning is more specific than "Recombinant Proteins".
This graph shows the total number of publications written about "Recombinant Proteins" by people in this website by year, and whether "Recombinant Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 29 | 29 | | 1997 | 0 | 29 | 29 | | 1998 | 1 | 41 | 42 | | 1999 | 2 | 28 | 30 | | 2000 | 4 | 28 | 32 | | 2001 | 3 | 32 | 35 | | 2002 | 1 | 42 | 43 | | 2003 | 6 | 34 | 40 | | 2004 | 4 | 37 | 41 | | 2005 | 7 | 59 | 66 | | 2006 | 4 | 39 | 43 | | 2007 | 3 | 32 | 35 | | 2008 | 3 | 36 | 39 | | 2009 | 5 | 32 | 37 | | 2010 | 6 | 35 | 41 | | 2011 | 3 | 31 | 34 | | 2012 | 2 | 27 | 29 | | 2013 | 3 | 35 | 38 | | 2014 | 3 | 33 | 36 | | 2015 | 3 | 32 | 35 | | 2016 | 3 | 20 | 23 | | 2017 | 2 | 25 | 27 | | 2018 | 4 | 24 | 28 | | 2019 | 4 | 18 | 22 | | 2020 | 3 | 21 | 24 | | 2021 | 3 | 13 | 16 | | 2022 | 0 | 4 | 4 | | 2023 | 0 | 9 | 9 | | 2024 | 1 | 4 | 5 | | 2025 | 0 | 13 | 13 | | 2026 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Recombinant Proteins" by people in Profiles.
-
Bermack C, Singh S, Pei G, Patel SP, Wang L, Yee C. First-in-human use of recombinant IL-7 to potentiate antigen-specific T cell therapy: a single patient case study. J Immunother Cancer. 2026 Apr 30; 14(4).
-
Robbins JO, Okrent AL, Grigore E, Leyngold MM, Morey GE, Leyngold IM. Long-Term Outcomes of Corneal Neurotization for Neurotrophic Keratopathy: A Dual-Center, Single-Surgeon Retrospective Study. Plast Reconstr Surg. 2026 Oct 01; 158(4):649-657.
-
Sagel SD, Vu P, Heltshe SL, Solomon GM, Kelly A, Pittman J, Rosenfeld M, Ratjen F. Elexacaftor/tezacaftor/ivacaftor is associated with long-term reduction in use of chronic respiratory therapies in cystic fibrosis. J Cyst Fibros. 2026 May; 25(3):450-456.
-
Weitz JI, Kithcart AP, O'Brien MP, Levy O, Marin E, Onisko M, Mohammadi KA, Li D, Meagher KA, Chang HH, Olenchock BA, Gutstein DE, Segers A, Roberts RS, Bonaca MP, Raskob GE. Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials. Lancet. 2025 11 29; 406(10519):2551-2563.
-
Rebhun RB, Cruz SM, York D, Mazcko CN, Razmara AM, Patkar S, Judge SJ, Sholevar CJ, Shah RK, Zamora AE, Al-Nadaf S, Vail DM, Fan TM, Burton JH, Luker ME, Skorupski KA, Lejeune AT, Woolard K, Stewart SL, Sparger EE, Young J, Cohen-Davidyan T, Huang E, Beck JA, Murphy WJ, Kent MS, Culp WTN, LeBlanc AK, Canter RJ. Phase 2 trial (NCI-COTC030) of adjuvant inhaled recombinant human IL-15 combined with amputation and adjuvant chemotherapy in dogs with appendicular osteosarcoma. Front Immunol. 2025; 16:1672790.
-
Chaudhry-Waterman N, Schardt TQ, Soderstrom RM, Warren BB, Buckvold S, Morgan G, Kim JS. Catheter-Directed Bivalirudin for Local Anticoagulation and Clot Dissolution in Children Requiring Mechanical Circulatory Support. ASAIO J. 2026 02 01; 72(2):e24-e28.
-
Markovic N, Budde E, Evans CT, Finch D, Xia Y, Huo Z, Han JH, Rech MA. Time to hemostatic agent administration increases mortality in veterans with factor Xa inhibitor-related intracranial hemorrhage. Am J Emerg Med. 2025 12; 98:201-206.
-
Rech MA, Budde E, Evans CT, Finch D, Xia Y, Huo Z, Han JH. Andexanet alfa increases 30-day thrombotic events relative to four-factor prothrombin complex concentrate for factor Xa inhibitors-related intracerebral hemorrhage in veterans. Am J Emerg Med. 2025 11; 97:97-102.
-
Buckner TW, Kessler C, Castaman G, Hermans C, Jiménez-Yuste V, Mahlangu J, Miesbach W, Oldenburg J, Recht M, Valentino LA, Wheeler AP, Pipe SW. Pain Reduction Following Eptacog Beta Treatment of Bleeding Episodes in Adolescents and Adults With Haemophilia A or B Complicated by Inhibitors. Haemophilia. 2025 Jul; 31(4):713-721.
-
Kahan RH, Palmer SK, Garoosi K, Gomez DA, Khechoyan DY, French B, Lowe K, Nguyen PD. Alveolar Bone Grafting: Outcomes Utilizing Synthetic HA/TCP and rhBMP-2 versus Autologous Graft Types. Plast Reconstr Surg. 2026 01 01; 157(1):129-138.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|